05/20/14 - 01:42 PM EDT
Provectus is supposed to hear back from the FDA this week about the request to grant PV-10 Breakthrough Therapy status for skin cancer. So far, Provectus has said nothing about the FDA's response.READ FULL POST
05/20/14 - 10:26 AM EDT
Japanese companies have a history of paying grossly inflated prices for U.S. assets, but the drug maker Eisai would have to be monumentally stupid -- and financially reckless -- to buy out its obesity drug partner Arena Pharmaceuticals.READ FULL POST
05/19/14 - 10:39 AM EDT
InterMune should have pirfenidone on the U.S. market in early 2015, but figuring out Boehringer's FDA strategy is more difficult.READ FULL POST
05/15/14 - 09:30 AM EDT
It's been five months since Northwest Biotherapeutics told investors that independent monitors were conducting an interim efficacy analysis of the phase III study of DC-Vax in patients with newly diagnosed glioblastoma multiforme (GBM.)READ FULL POST
05/14/14 - 03:35 PM EDT
Lion Bio received an SEC subpoena related to the Galena DreamTeam investigation.READ FULL POST
05/14/14 - 10:39 AM EDT
The phase I/II study will combine Bristol's PD-1 checkpoint inhibitor nivolumab with Celldex's CD27-targeted antibody varlilumab, also known as CDX-1127.READ FULL POST
05/12/14 - 06:24 PM EDT
Telik never recovered from hiding the premature deaths of ovarian cancer patients treated with its experimental drug Telcyta in 2007READ FULL POST
05/12/14 - 10:19 AM EDT
J.P. Morgan analyst Geoff Meacham issued a cautiously optimistic note about the biotech sector this morning. While investor sentiment remains "fragile," and volatility continues to be high, Meacham believes the worst of the selling is over.READ FULL POST
05/08/14 - 09:05 AM EDT
Chelsea CEO Joe Oliveto and his team deserve a lot of credit for cleaning up some messy Northera clinical trials, scoring at the FDA advisory panel, securing the drug's approval and now delivering on the exit strategy that everyone wanted.READ FULL POST
05/07/14 - 12:49 PM EDT
Even at $86 million in 2014 Iclusig sales, Ariad trades at a lofty and unjustified 13 times enterprise value. For comparison's sake, Medivation's EV/sales multiple is 9 -- and that's only counting U.S. sales of its growing prostate cancer drug Xtandi.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.